Are Companies Leaving Money On The Table When Seeking Reimbursement?

This article takes a look at a study involving the data on reimbursement submissions, decisions, and re-submissions, that was recently presented at the ISPOR European Congress in Dublin. What they found was really quite interesting-62% of the HTAs that were rejected on the first submission never resubmitted! Leaves one wondering -are the pharmaceutical companies leaving money on the table while we the public miss out on potentially important new drugs? Read full article here. (Source: Context Matters, 11/22/13).